Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04964466

Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis

Conditions: Bone Loss

Sex: All
Ages: 18 Years – 99 Years
Healthy volunteers: Yes
Enrollment: 5
Sponsor: University of Alabama at Birmingham

Location: University of Alabama at Birmingham Birmingham Alabama

Summary

This study is seeking to evaluate that platelet-derived growth factor-BB (PDGF-BB) is a proven wound healing and osteogenic protein that plays a critical role in wound healing and previous research has demonstrated a non-linear response where higher dosages produced less effect. As Platelet Rich Fibrin (PRF) contains numerous platelets, it contains PDGF-BB, but at levels lower than in the commercially available product and with inter-individual variation, GEM21S. To achieve both ideal handling and achieve ideal levels of PDGF-BB, there is a rationale to add GEM 21S recombinant human platelet-derived growth factor-BB (rhPDGF) to a bone graft prior to making "sticky bone".

Eligibility Criteria

Inclusion Criteria: * English speaking * At least 18 years old * Able to read and understand informed consent document * Systemically healthy, non-smoker, no medications Exclusion Criteria: * Non-English speaking * Less than 18 years old * Smokers/tobacco users (\>10 cigarettes/day) * Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting healing

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04964466). StuddyBuddy aggregates publicly available trial information.